Company: DARE
Filing Date: 2025-12-01
Form Type: 8-K
Source: 0001493152-25-025491
Chunk: 1

Company: Dare Bioscience, Inc.
Filing Date: 2025-12-01
Form: 8-K
Item: Item 1.02
Chunk 1
---
 continue
without modification. In accordance with the Investigational Device Exemption for Ovaprene, we provided an annual report to the U. S.
Food and Drug Administration (“ FDA”) with data collected from the study through September 15, 2025 regarding safety, tolerability
and pregnancy experiences. Such data was consistent with the data analyzed by the DSMB during the July 2025 planned interim analysis.
We intend to maintain active recruitment at five study sites, supported by grant funding we received in November 2024. We currently anticipate
enrollment will be completed in 2026, and plan to provide further updates regarding anticipated enrollment and study completion targets
in 2026.